MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

How Are Medtech's Emerging Markets Faring?—Abbott

How Are Medtech's Emerging Markets Faring?—Abbott
Abbott's Take on Emerging Markets

Abbott's Take on Emerging Markets

"Every morning we get up, we see CNBC. Everybody brings their hands about China, but whether China is 7% growth or 6% growth, 6% is way bigger than the rest of the world. It's a fundamentally strong market for us as [are] practically all of these emerging markets.

Now, the oil-based economy, the ones we were extremely dependent on oil, take Venezuela--okay, there are different stories. And the volatility, unreliability and sustainable market there is different than just about anywhere in the world . . . 

. . .  As many of you know, market conditions in Venezuela have become more challenging including high inflation, increasing price and margin controls, regulations on import, and slowing demand.

As a result, our forecast assumes a significantly lower contribution from Venezuela operation in 2016."

Miles White, Abbott chairman and CEO, according to a Seeking Alpha transcript of the company's fourth quarter earnings call

Get inspired to innovate during Massachusetts Medtech Week--register for BIOMEDevice Boston 2016, April 13-14.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.